Fund moves
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KMDA · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Kamada (KMDA) · oqro.io/stocks/KMDA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Kamada is on record in SEC filings since 2006.
No open-market sale by an insider of Kamada (KMDA) was filed with the SEC in the last 90 days.
No trade in Kamada (KMDA) was disclosed by a member of Congress in the last 12 months.
Kamada's next results are expected on Mar 9, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$7.74−0.09 (−1.15%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
+15.9% (+$1.06) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $6.68 on Nov 20, 2025 to $7.74 on Nov 20, 2026 (+15.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 3 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Rehovot, Israel. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
+15.9%
Market value
$446M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 166K shares sold short (0.3% of shares outstanding), −16.1% vs the previous count, 2.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed May 12, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Feb 11, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 12, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Jul 30, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest annual report filed Mar 11, 2026, compared with the one filed Mar 5, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Mar 11, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 11, 2026. Read the filing
+10% on the year before ($141M)
+24% on the year before ($19.5M)
−0.9% on the year before ($101M)
+18% on the year before ($25M)
+30% on the year before ($18.6M)
+14% on the year before ($9.46M)
+91% on the year before ($4.94M)
+183% on the year before ($2.38M)
−9.7% on the year before ($62K)
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 12,000 words.
We are a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. Our strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of our commercial portfolio, including continued investment in the commercialization and life cycle management of our Proprietary Products, which consist of six FDA-approved specialty plasma-derived products: KEDRAB, GLASSIA, CYTOGAM, WINRHO SDF, VARIZIG, and HEPAGAM B, as well as KAMRAB, and two types of equine-based ASV products.
Source: SEC EDGAR, Form 20-F filed Mar 11, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 26 more headings in the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, KMDA is up 13.2% and the index fund is up 4.5%: 9 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KMDA moves
Beta 1.0 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
No Schedule 13D or 13G filing on KMDA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last results
—
Next results, expected
Mar 9, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
Not enough history
From Kamada's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Kamada's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 44.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (16.1% on ATS, 28.8% with other brokers), above its 26-week average of 39.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (17.9%), IBKR ATS (14.5%), INTELLIGENT CROSS LLC (13.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind